Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Industry News

BioMérieux acquires Day Zero Diagnostics

June 18, 2025—BioMérieux will acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics.

Proscia releases laboratory leadership report

June 16, 2025—Proscia has published a report in which it partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories.

More than 100,000 patients tested with MeMed BV

June 9, 2025—MeMed announced that more than 100,000 patients have been tested with MeMed BV, the company’s flagship diagnostic that distinguishes between bacterial and viral infections based on the body’s immune response.

Pillar raises $34.5 million in funding

May 27, 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, including a strategic investment from Illumina and structured financing from Soleus Capital and investments from existing investors.